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ABSTRACT
The combination of cisplatin and gemcitabine is the standard first-line treatment of metastatic biliary tract cancer (BTC) 
patients. The benefit of second-line chemotherapy in these patients is controversial. This study aims to evaluate the activity 
of FOLFIRI (fluorouracil and irinotecan) after failure to the first-line platinum and gemcitabine-based chemotherapy in 
metastatic BTC patients. We present a single-institution, retrospective cohort study. Patients with locally advanced or 
metastatic BTC who progressed after at least one line of chemotherapy, consecutively treated at our Institution between 
2007 and 2017 were included. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were 
overall survival (OS), clinical benefit rate (CBR) and safety profile of FOLFIRI. Twelve patients were included in the analysis, 
with a median follow up of 5 months (95% CI 2.77-7.20). The median number of cycles received was 3 (range 1 to 9). 
Four grade 3 toxicities were recorded; no grade 4 toxicities and no treatment-related deaths occurred. The median PFS 
was 1.7 months (95% CI; 0.66-2.67), and median OS was 5 months (95% CI; 2.77-7.20). Two patients presented stable 
disease, providing a CBR of 17%. We concluded that FOLFIRI presented a favorable toxicity profile and a modest activity 
in metastatic BTC patients who had progressed to platinum and gemcitabine and may be considered in patients who 
are able to tolerate additional lines of chemotherapy. Immunotherapy and targeted therapies selected according to the 
tumoral genomic profile are promising alternatives to improve the outcomes of second-line treatment in BTC. 
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INTRODUCTION
Biliary tract cancer (BTC) is a rare tumor, with 
an estimated incidence of 1 to 2 new cases per 
100,000 people annually in the United States.1 
In Belgium, around 350 new cases are diagnosed 
every year, and BTC is responsible for 0.5% of the 
cancer deaths in males and 0.8% in females.2 Surgery 
provides the only possibility of curative treatment for 
BTC patients, although it is feasible in only 20% of 
the cases because 80% of the patients present with 
locally advanced unresectable disease or metastases at 
diagnosis.3-5 The prognosis of patients with metastatic 
BTC is dismal, with 5-year survival rates of less than 1%.6
Chemotherapy is the mainstay treatment of 
metastatic BTC, and its administration aims to promote 
symptom relief, improve the quality of life and prolong 
the overall survival of the patients.7 The combination 
of cisplatin and gemcitabine has been established as 
the standard first-line treatment of metastatic BTC.8 
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However, when disease progression occurs, there is 
no high-quality data to support the administration of 
second-line chemotherapy to BTC patients.4,9,10 Indeed, 
studies evaluating second-line treatments are scarce, and 
the benefit of chemotherapy over best supportive care in 
this scenario has never been demonstrated.9,10 Therefore, 
new strategies are needed to improve these outcomes.
Metastatic pancreatic cancer shares some 
histological and molecular characteristics with BTC.11 
The FOLFIRINOX regimen (fluorouracil, irinotecan 
and oxaliplatin) has robust activity in the first-line 
treatment of metastatic pancreatic cancer patients, 
and its superiority over gemcitabine alone has been 
demonstrated in a phase III study.12 The results of 
FOLFIRINOX in pancreatic cancer generated interest in its 
potential activity also in BTC. Indeed, in a retrospective 
study with 12 metastatic BTC patients in different 
lines of treatment, FOLFIRINOX yielded a 41.7% 
clinical benefit rate (CBR) and a median progression-
free survival (PFS) of 9 weeks.13 Ongoing studies are 
evaluating FOLFIRINOX in metastatic BTC patients 
[NCT03291899; NCT03778593; NCT02591030; 
NCT02456714; NCT01494363]. Notably, FOLFIRINOX 
is an intensive chemotherapy regimen that comprises 
3 cytotoxic drugs administered at 14-day cycles. Thus, 
the risk of adverse events is relevant and represents a 
potential concern for the development of this regimen 
in BTC, especially for frail patients.12 As an alternative, 
the agents that compose FOLFIRINOX can be combined 
as doublets (fluorouracil and oxaliplatin [FOLFOX] or 
fluorouracil and irinotecan [FOLFIRI]) to minimize the 
risks of adverse events, however more data on the 
efficacy of FOLFOX and FOLFIRI in BTC is needed.14
The FOLFIRI regimen (fluorouracil and irinotecan) 
arises as a potentially effective and less toxic alternative of 
second line-treatment due to the absence of oxaliplatin, 
which commonly causes hematological toxicities and 
peripheral neuropathy, the latest being potentially a 
limiting condition for patients suffering from neuropathy 
derived from a first-line gemcitabine-cisplatin regimen.14,15 
As a consequence, ongoing studies are evaluating 
FOLFIRI as a second-line treatment in metastatic BTC 
patients. [NCT03110510; NCT03464968] However, the 
administration of FOLFIRI after failure to a platinum and 
gemcitabine-based regimen has been only reported in 
few retrospective series; therefore more evidence on 
the activity of FOLFIRI in this setting is needed.10,16-18 
The present study aims to assess and describe the 
activity of FOLFIRI after failure to a first-line platinum and 
gemcitabine regimen in metastatic BTC patients.
METHODS
Objectives
The primary objective of this study is to assess 
the activity of FOLFIRI in metastatic BTC patients 
who experienced disease progression after first-line 
platinum and gemcitabine-based chemotherapy. 
The primary endpoint is PFS, defined as the time 
between the first day of the first FOLFIRI cycle and the 
occurrence of disease progression or death due to any 
cause, whichever occurred first.
The secondary endpoints are overall survival 
(OS) - defined as the time between the first day of the 
first FOLFIRI cycle and death due to any cause; CBR - 
defined as the rate of patients presenting a complete 
response, a partial response or stable disease (per 
Response Evaluation Criteria in Solid Tumors [RECIST] 
criteria version 1.1) at the first imaging assessment 
performed to evaluate FOLFIRI response; and safety 
profile – defined as the frequency of grade ≥3 toxicities 
presented between the first day of the first cycle and 30 
days after the last administration of FOLFIRI. Toxicities 
were classified and graded according to the Common 
Terminology Criteria for Adverse Events (CTCAE) version 
4.0, which was the latest version available at the time 
of FOLFIRI administration.
Patient’s Selection
This is a single-institution, retrospective cohort 
study performed at the Medical Oncology Department 
of Institut Jules Bordet, Brussels, Belgium. Patients 
with a histologically confirmed diagnosis of BTC 
of any histological type; with metastatic disease 
confirmed by imaging exams or locally advanced 
disease considered not suitable for surgery; who 
presented disease-progression as defined per RECIST 
after at least one line of chemotherapy including 
platinum and gemcitabine; and consecutively treated 
at our Institution between 2007 and 2017 were 
included. A detailed review of electronic records from 
each patient was performed to extract data for the 
study. This protocol has been submitted to the local 
ethics committee of Institut Jules Bordet and received 
approval before the study initiation.
To assess the  CBR, we considered the results of 
the first radiological exam (computerized tomography 
[CT], magnetic resonance imaging [MRI] or fluorine-18 
f luoro-2-deoxy-D-glucose pos i t ron emiss ion 
tomography/computerized tomography [FDG–PET/CT]) 
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performed after the initiation of FOLFIRI, which 
was requested according to the treating’s physician 
discretion. Routinely, imaging exams are performed 
every 2 to 3 chemotherapy cycles at our Institution 
to assess treatment response, which is evaluated by 
RECIST version 1.1. Chemotherapy is administered 
until the occurrence of disease progression, limiting 
toxicities or consent withdrawn by the patient, 
whichever occurs first. The standard FOLFIRI regimen 
administered at our Institution consists in fluorouracil 
400mg/m2 bolus on D1 then 2400 mg/m2 on a 48h 
protracted infusion D1-2, leucovorin 200 mg/m2 on D1 
and irinotecan 180 mg/m2 on D1 every 14 days, with 
each administration being considered 1 cycle.
Statistical Analysis
PFS and OS were calculated with the Kaplan-Meier 
method, and median values were reported with their 
respective 95% confidence intervals (CI). Patients’ 
characteristics were reported with their respective 
median and/or range values when applicable. All the 
statistical analyses were performed using the R software 
version 4.4.1.
RESULTS
From all the patients with metastatic BTC who 
were consecutively treated between 2007 and 2017 
at our Institution, twelve patients who received 
at least one cycle of FOLFIRI after progression to 
first-line chemotherapy were identified and considered 
eligible. The median age was 60 years, 75% had an 
Eastern Cooperative Oncology Group Performance 
Status (ECOG) ≤1, 100% presented extrahepatic 
metastases and 92% had only 1 previous line of 
chemotherapy administered for the treatment of 
metastatic disease. All patients had received platinum 
and gemcitabine-based chemotherapy as the first-line 
treatment of metastatic disease. Patient’s characteristics 
are illustrated in Table 1.
Table 1. Patient’s characteristics
Variable Number (%) Variable Number (%)
Age (years) Staging
Median 60 Metastatic 12 (100%)
Range (37 - 82) Locally advanced 0
Sex Sites of metastases
Male 6 (50%) Hepatic only 0
Female 6 (50%) Extrahepatic 12 (100%)
ECOG Previous biliary drainage 2 (17%)
0 4 (33%) Previous surgery to resect primary tumor 2 (17%)
1 5 (42%) Previous radiotherapy in the primary tumor 0
2 1 (08%) Previous radiotherapy in metastases 7 (58%)
3 2 (17%) Previous treatment with SIR-spheres 1 (08%)
Smoking history Previous chemotherapy lines
Current smoker 4 (33%) One 11 (92%)
Former smoker 1 (08%) Two 1 (08%)
Never smoker 7 (58%) FOLFIRI cycles
Histology Median 3
Adenocarcinoma 12 (100%) Range (1 - 9)
Others 0 FOLFIRI dose reduction
Primary tumor Yes 3 (25%)
Gallbladder 1 (08%) No 9 (75%)
Intrahepatic 9 (75%) FOLFIRI cycle delays
Extrahepatic 2 (17%) Yes 2 (17%)
No 10 (83%)
Reason for FOLFIRI discontinuation
Progressive disease 11 (92%)
Adverse events 1 (08%)
ECOG, Eastern Cooperative Oncology Group performance status scale; SIR-spheres, microspheres impregnated with 90Ytrium, 
a beta radiating isotope.
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Safety Profile
The median number of FOLFIRI cycles received by 
the patients was 3 (range 1 to 9). In 3 patients (25%), 
a dose reduction was necessary at any point due to 
toxicities. Cycle delays occurred in 2 patients (17%), 
and 1 patient (8%) had to discontinue FOLFIRI due to 
adverse events. (Table 1).
Four grade-3 toxicities were recorded: diarrhea (1), 
emesis (1), and fatigue (2); no grade-4 toxicities and 
no treatment-related deaths occurred. (Table 2)
Efficacy
No loss of follow-up occurred, and all patients 
were followed until the occurrence of an event 
(death or progression) at our Institution. The median 
follow-up since the first day of FOLFIRI administration 
was 5 months (95% CI 2.77-7.20).
Progression-Free Survival (PFS)
Eleven patients (92%) discontinued FOLFIRI due 
to disease progression. All patients included in the 
analysis presented disease progression confirmed by 
imaging exams. The median PFS achieved with FOLFIRI 
was 1.7 months (95% CI; 0.66-2.67). (Figure 1)
Overall Survival (OS)
All patients included in the analysis had died 
before the date of data collection for this study. 
The median OS from the date of diagnosis of BTC 
until death was 16 months (95% CI; 9.97-22.06) 
(Figure 2). The median OS from the first day of FOLFIRI 
administration until death (median OS with FOLFIRI) 
was 5 months (95% CI; 2.77-7.20) (Figure 3).
Clinical Benefit Rate
At the moment of the first evaluation of treatment 
response, 10 patients (83%) presented radiological 
evidence of progressive disease, whereas 2 patients 
presented stable disease and continued FOLFIRI, 
providing a CBR of 17%.
Table 2. Adverse events grade ≥3 presented with 
FOLFIRI
Adverse event
Number of 
patients (%)
Number of 
patients (%)
Grade 3 Grade 4
Anemia 0 0
Thrombocytopenia 0 0
Neutropenia 0 0
Febrile neutropenia 0 0
Diarrhea 1 (08) 0
Emesis 1 (08) 0
Fatigue 2 (17) 0
Transaminases elevation 0 0
Bilirubin elevation 0 0
Creatinine elevation 0 0
Rash 0 0
Hand-foot syndrome 0 0
Mucositis 0 0
Figure 1. Kaplan Meier curve of progression-free survival with FOLFIRI.
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DISCUSSION
The populat ion of our study ref lects the 
characteristics of the patients with metastatic BTC 
reported in other series in terms of age, tumor primary 
site, and histology, and the OS of 16 months observed 
is in-line with data reported in the medical literature.19 
The administration of FOLFIRI was feasible and 
presented a manageable toxicity profile, with clinically 
relevant adverse events being observed in the minority 
of the patients. The short median PFS and OS and the 
modest CBR observed in our study suggest that FOLFIRI 
has limited activity as second-line chemotherapy in 
metastatic BTC patients.
The combination of cisplatin and gemcitabine is 
the standard-of-care first-line treatment of metastatic 
BTC patients, based on the results of the phase III 
study ABC-02, which demonstrated an overall survival 
benefit with cisplatin-gemcitabine compared to 
gemcitabine alone (median OS 11.7 vs. 8.1 months 
respectively; hazard ratio [HR] 0.64; 95% CI, 0.52-0.80; 
p<0.001).4,8 Unfortunately, disease progression 
invariably occurs after first-line chemotherapy, and 
Figure 2. Kaplan Meier curve of overall survival since the moment of diagnosis of biliary tract cancer.
Figure 3. Kaplan Meier curve of overall survival with FOLFIRI.
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no second-line treatment has been established as a 
standard for metastatic BTC patients so far.9,10 Notably, 
disease progression is generally associated with 
fatigue, jaundice, weight loss, pain and a decrease in 
performance status.19 As a consequence of this clinical 
deterioration that frequently occurs at progression, the 
administration of second-line treatments is feasible 
only in a minority of the patients, with best supportive 
care being recommended in most of the cases.9,10,20,21
The evidence to support the recommendation 
of second-line chemotherapy in BTC patients is 
scarce, consisting mainly in retrospective series and 
phase II studies.9,10 Second-line chemotherapy can be 
considered in patients who present a good performance 
status and a low predicted risk of toxicities, although its 
efficacy is modest.9,10,21 The regimens most frequently 
administered are those based on fluoropyrimidines and 
taxanes, which yield response rates of around 10% 
and median PFS rates of approximately 3 months.9,10 
Polychemotherapy regimens are associated with an 
increased risk of adverse events and do not seem 
to increase response rates or PFS in comparison to 
single-agent chemotherapy.10 Targeted-therapies such 
as bevacizumab (monoclonal antibody that targets the 
vascular endothelial growth factor [VEGF]), erlotinib 
(tyrosine kinase inhibitor that blocks the epithelial 
growth factor receptor [EGFR]), cetuximab and 
panitumumab (monoclonal antibodies targeting the 
EGFR) presented also a modest activity as second-line 
treatments in BTC patients.22-29
The use of FOLFIRI after failure to first-line 
chemotherapy has been evaluated in retrospective 
series, with response rates of around 11% and a median 
PFS of approximately 3 months (Table 3).16-18,30,31 In the 
largest of these series, 98 patients who received 
FOLFIRI after progression on first-line platinum and 
gemcitabine chemotherapy were evaluated. Sixty-five 
out of the 98 patients had response assessments 
documented in their medical records, with 11% 
presenting a partial response and 35% presenting 
stable disease. The median PFS and OS were 2.4 and 
6.6 months respectively.31 In a prospective single-arm 
phase II study that evaluated FOLFIRI as the first-line 
treatment of 30 patients with unresectable or 
metastatic BTC, the response rate was 10%, whereas 
10% of the patients presented stable disease; the 
median PFS was 2.8 months for patients with an 
intrahepatic primary tumor and 5.2 months for those 
with extrahepatic tumors.30 The results from our study 
are thus similar to those reported in the literature, 
supporting the concept that the activity of FOLFIRI in 
metastatic BTC is at best modest, although a subset 
of patients may derive benefit from this treatment.9,10
The main chal lenges in the treatment of 
metastatic BTC are the small proportion of patients 
that are eligible to receive a second line treatment 
when disease-progression occurs, the absence of 
effective treatments after the first-line and the lack 
of biomarkers to predict which patients benefit from 
treatment.9,10,19 Promising strategies to overcome 
these limitations are under evaluation. As an example, 
immunotherapy is based on the rationale that the 
activation of the immune system can generate an anti-
tumor immune response.32 This concept has proven to 
be effective in several malignancies and is currently 
being also investigated in metastatic BTC patients.33 
Table 3. Studies reporting outcomes of metastatic biliary tract cancer patients treated with FOLFIRI
1st author year Regimen N Design Line ORR mPFS mOS
Feisthammel30
2007
FOLFIRI 30 Single-arm 
PHASE II
1st 10% 2.8 m (intrahepatic)
5.2 m (extrahepatic)
5.4 m (intrahepatic)
9 m (extrahepatic)
Brieau16
2015
 FOLFIRI 64 b Retrospective 2nd 11.5% 2.6 m 6.1 m
Moretto17
2013
FOLFIRI 24 b
30 p
Retrospective 38% 2nd 42.9% 
(CBR)
3.5 m 6.2 m
Sebbagh18
2015
FOLFIRI 52 Retrospective 2nd N/A 3.2 m 8.4 m
Mizrahi31
2019
FOLFIRI 98 Retrospective 2nd and 
beyond
11% 2.4 m 6.6 m
Caparica
2019
FOLFIRI 12 Retrospective 2nd and 
beyond
17%
(CBR)
1.7 m 5 m
b = biliary; CBR = clinical benefit rate; m = months; mPFS = median progression-free survival; mOS = median overall survival; 
N = number of patients; ORR = overall response rate; p = pancreatic; N/A = not available.
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In the preliminary reports of two phase II studies that 
enrolled metastatic BTC patients who had received 
several lines of chemotherapy, the anti-programmed 
death-1 receptor antibodies pembrolizumab and 
nivolumab presented response rates of 5.8% and 17%, 
respectively. Interestingly, the median duration of 
response was not reached in both studies, suggesting 
that patients who respond to immunotherapy may 
present a long-term benefit with this treatment.34,35
Notably, BTC have a heterogeneous genomic 
profile, and different  abnormalities were found 
in these tumors, such as mutations/amplifications 
in the genes of the human epidermal growth 
factor (HER) family, fibroblast growth factor (FGFR) 
mutations/rearrangements, isocitrate dehydrogenase 
(IDH) mutations and hyperexpression or mutations in 
the genes involved in the mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) 
pathways.36 Targetable alterations, meaning those 
genomic abnormalities for which a potential therapy 
exists, were found in 68% of the cases in one study 
with 34 metastatic BTC patients.37 Interestingly, the 
genomic profile of BTC varies according to the site 
of origin of the primary tumor: while IDH and FGFR 
alterations are more frequent in intrahepatic tumors, 
abnormalities in the genes of the HER family are more 
common in extrahepatic and gallbladder tumors.36 
The incorporation of tumoral genomic profile as a 
stratification factor in studies evaluating targeted 
therapies arises as a promising strategy to optimize the 
treatment of BTC.37 As an example, the combination of 
a BRAF inhibitor (dabrafenib) with a mitogen-activated 
extracellular kinase (MEK) inhibitor (trametinib) yielded 
a median PFS of 9.2 months in a phase II study that 
enrolled 33 patients with BRAF mutated metastatic 
BTC. Partial responses were observed in 14 patients 
(42%), while stable disease occurred in 15 patients 
(45%).38 Although direct comparisons between 
different studies are precluded, these results are more 
robust than the ones observed in our study and in the 
literature with second-line chemotherapy in general.9,10
The potential limitations of the present study 
need to be considered when interpreting our findings. 
The retrospective character of our series increases 
the risks of bias and missing data, limiting the 
assessment of toxicities and treatment response 
since all the information was retrieved from the data 
reported in patient’s medical records. Since most 
patients who experience progressive disease after 
first-line chemotherapy are too debilitated to receive a 
second-line treatment, the population included in our 
study may be composed of selected patients with good 
prognostic features or with indolent tumors who were 
eligible to receive additional chemotherapy. The small 
sample size reduces the robustness of our analyses, 
and a logistic regression model that was originally 
pre-planned to seek for potential prognostic or 
predictive factors could not be performed. All patients 
were treated at a single tertiary cancer center in 
Belgium, which possesses high-quality facilities and 
vast expertise in the management of BTC, a fact 
that may limit the extrapolation of these results to 
low-resource scenarios. However, due to the paucity 
of studies on the topic, our findings are important to 
provide additional data on the activity of FOLFIRI after 
progression to first-line chemotherapy in metastatic 
BTC patients.
In conclusion, FOLFIRI presented a manageable 
toxicity profile but a modest activity in metastatic 
BTC patients who had progressed to platinum and 
gemcitabine chemotherapy and may be considered 
an option for patients who can tolerate additional 
lines of chemotherapy. The enrolment of metastatic 
BTC patients in clinical trials must be encouraged, 
due to the paucity of effective treatments in this 
scenario. Immunotherapy and targeted therapies 
selected according to the tumoral genomic profile 
arise as promising alternatives to improve the efficacy 
of second-line treatment in BTC patients.
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